$300 Million is the total value of Decheng Capital Management III (Cayman), LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 68.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALPN | New | Alpine Immune Sciences, Inc. | $76,809,898 | – | 6,708,288 | +100.0% | 25.63% | – |
| ZNTL | Zentalis Pharmaceuticals Inc. | $42,117,635 | -28.9% | 2,099,583 | 0.0% | 14.06% | -24.3% | |
| Buy | Aura Biosciences, Inc. | $18,243,928 | +403.6% | 1,163,123 | +296.5% | 6.09% | +436.0% | |
| New | ROIVANT SCIENCES LTD | $17,049,296 | – | 1,459,700 | +100.0% | 5.69% | – | |
| Sell | ACELYRIN INC(NSM) | $15,746,384 | -51.5% | 1,548,317 | -0.4% | 5.26% | -48.4% | |
| RCUS | Arcus Biosciences, Inc | $15,612,731 | -11.6% | 869,790 | 0.0% | 5.21% | -6.0% | |
| TXG | 10x Genomics, Inc. | $14,831,603 | -26.1% | 359,554 | 0.0% | 4.95% | -21.4% | |
| ARGX | Argenx SE | $13,484,919 | +26.1% | 27,429 | 0.0% | 4.50% | +34.2% | |
| PACB | Pacific Biosciences of California, Inc. | $12,223,331 | -37.2% | 1,463,872 | 0.0% | 4.08% | -33.2% | |
| ILMN | Illumnia, Inc. | $11,100,324 | -26.8% | 80,859 | 0.0% | 3.70% | -22.1% | |
| LNTH | New | LANTHEUS HOLDINGS INC(NMS) | $9,879,778 | – | 142,196 | +100.0% | 3.30% | – |
| HZNP | Horizon Therapeutics PLC | $9,127,941 | +12.5% | 78,900 | 0.0% | 3.05% | +19.7% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $8,814,500 | -27.6% | 850,000 | 0.0% | 2.94% | -22.9% | |
| IMGN | New | IMMUNOGEN INC | $6,600,016 | – | 415,880 | +100.0% | 2.20% | – |
| SGEN | New | SEAGEN INC | $4,882,420 | – | 23,014 | +100.0% | 1.63% | – |
| Cue Health Inc. | $3,969,798 | +19.5% | 8,980,909 | 0.0% | 1.32% | +27.2% | ||
| BYSI | New | BeyondSpring Inc. | $3,966,514 | – | 4,958,143 | +100.0% | 1.32% | – |
| TERN | Terns Pharmaceuticals, Inc. | $3,592,854 | -42.5% | 714,285 | 0.0% | 1.20% | -38.8% | |
| EQ | Equillium Inc. | $3,291,008 | -1.3% | 4,447,308 | 0.0% | 1.10% | +5.0% | |
| Aadi Bioscience, Inc. | $2,547,432 | -29.2% | 526,329 | 0.0% | 0.85% | -24.7% | ||
| ATRC | New | AtriCure Inc. | $2,026,144 | – | 46,259 | +100.0% | 0.68% | – |
| SCYX | Scynexis Inc. | $1,266,665 | -22.7% | 555,555 | 0.0% | 0.42% | -17.7% | |
| MRSN | Mersana Therapeutics, Inc. | $1,148,420 | -61.4% | 904,268 | 0.0% | 0.38% | -58.9% | |
| New | Pyxis Oncology, Inc (formerly Apexigen) | $650,352 | – | 326,810 | +100.0% | 0.22% | – | |
| New | GeneDx Holdings Corp. | $377,118 | – | 103,604 | +100.0% | 0.13% | – | |
| ACET | Sell | Adicet Bio, Inc. | $274,275 | -77.7% | 200,201 | -60.4% | 0.09% | -76.1% |
| NBSE | Exit | NeuBase Therapeutics, Inc. | $0 | – | -50,000 | -100.0% | -0.03% | – |
| Exit | GeneDx Holdings Corp. | $0 | – | -103,604 | -100.0% | -0.19% | – | |
| Exit | Apexigen, Inc. | $0 | – | -1,894,551 | -100.0% | -0.26% | – | |
| Exit | AtriCure Inc. | $0 | – | -46,259 | -100.0% | -0.72% | – | |
| SGEN | Exit | Seagen Inc. | $0 | – | -23,014 | -100.0% | -1.39% | – |
| Exit | BeyondSpring Inc. | $0 | – | -4,958,143 | -100.0% | -1.84% | – | |
| Exit | ROIVANT SCIENCES LTD | $0 | – | -1,459,700 | -100.0% | -4.62% | – | |
| ALPPRNCL | Exit | Alpine Immune Sciences, Inc. | $0 | – | -6,708,288 | -100.0% | -21.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-12-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-20 |
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.